Foolish Preview: Bristol-Myers Squibb

In the following video, Motley Fool health-care analyst David Williamson takes investors through what to expect from Bristol-Myers Squibb's upcoming earnings report and the important things to watch from this company moving forward.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Foolish Preview: Bristol-Myers Squibb originally appeared on Fool.com.

David Williamson owns shares of Pfizer. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.